ReviewiMetaOmics2024
A glimpse into the future: Integrating artificial intelligence for precision HER2-positive breast cancer management.
Review in iMetaOmics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Multi-omics and machine learning reveal DPPC as a key contributor to colorectal cancer progression and tumor immune microenvironment remodeling.Journal of translational medicine · 2026Article
- Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy.Oncology research · 2026Review
- Explainable machine learning for breast mass characterization and malignancy risk stratification: multimodal integration of AI-derived structured digital breast tomosynthesis features and peripheral blood immune-inflammatory biomarkers.Frontiers in cell and developmental biology · 2026Article
- 99mTc-FAPI-YQ3 SPECT/CT for characterizing FAPI uptake phenotypes and metabolic-stromal heterogeneity in advanced differentiated thyroid carcinoma: a prospective single-center imaging-radiomics study.Frontiers in immunology · 2026Observational
- Precision prevention of colorectal neoplasia in patients undergoing hemorrhoid surgery: an explainable machine learning model for identifying the risk of precancerous neoplastic polyps.Frontiers in cell and developmental biology · 2026Article
- AI-Driven predictive modeling of cervical intraepithelial neoplasia severity: a comprehensive analysis with clinical adoption frameworks.BMC cancer · 2025Article
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Paracrine Orchestration of Tumor Microenvironment Remodeling Induced by GLO1 Potentiates Lymph Node Metastasis in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Artificial Intelligence-Based Pathology to Assist Prediction of Neoadjuvant Therapy Responses for Breast Cancer.Cancer medicine · 2025Review
- Clinical approaches to overcome PARP inhibitor resistance.Molecular cancer · 2025Review
- HER2 prognostic values in non-muscle-invasive bladder cancer: a step towards personalized treatment for BCG instillation.Discover oncology · 2025Article
- Single-cell analysis unveils cell subtypes of acral melanoma cells at the early and late differentiation stages.Journal of Cancer · 2025Article
- Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications.Research (Washington, D.C.) · 2025Review
- Integrative single-cell and spatial transcriptomics uncover ELK4-mediated mechanisms inFrontiers in immunology · 2025Article
- Revealing key regulatory factors in lung adenocarcinoma: the role of epigenetic regulation of autophagy-related genes from transcriptomics, scRNA-seq, and machine learning.Frontiers in pharmacology · 2025Article
- Single-cell transcriptomics identifies FOSL1-regulated IGFBP3+ melanoma subtype as a neuro-immunoregulatory signaling hub facilitating tumor progression.Frontiers in immunology · 2025Article
- Multidimensional transcriptomics based to illuminate the mechanisms of taurine metabolism in immune resistance of pancreatic cancer.Frontiers in immunology · 2025Article
- Editorial: The insights of multi-omics into the microenvironment after tumor metastasis: a paradigm shift in molecular targeting modeling and immunotherapy for advanced cancer patients.Frontiers in oncology · 2025Article
- The cellular signaling crosstalk between memory B cells and tumor cells in nasopharyngeal carcinoma cannot be overlooked: Their involvement in tumor progression and treatment strategy is significant.Journal of Cancer · 2025Article
- The diagnosis and management of small and indeterminate lymph nodes in papillary thyroid cancer: preoperatively and intraoperatively.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC), specifically HER2-positives subtype, has a poor prognosis. Nevertheless, the development of anti-HER2 therapy yielded satisfactory outcomes. Therefore, evaluating patient HER2 status and ascertaining responsiveness to anti-HER2 therapy is crucial. The advent of deep learning has propelled the artificial intelligence (AI) revolution, leading to an increased applicability of AI in predictive models. In the field of medicine, AI is an emerging modality that is gaining momentum for facilitating cancer diagnosis and treatment, particularly in the effective management of breast cancer. This study aims to provide a comprehensive review of current diagnostic and predictive models that utilize data obtained from histopathological slides, radiomics, and HER2 binding sites. Advancements and practical applications of these models were also evaluated. Additionally, we examined existing obstacles that AI encounters for anti-HER2 therapy. We also proposed future directions for integrating AI in assessing and managing anti-HER2 therapy. The findings of this study offer valuable insights into the evaluation of AI-based anti-HER2 therapy, emphasizing key concepts and obstacles that, if addressed, could facilitate the integration of AI-assisted anti-HER2 therapy. The integration of AI has the potential to enhance the precision and customization of screening and treatment protocols for HER2+ breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.